(Press-News.org) CHICAGO – In a two year randomized trial, patients with symptomatic knee osteoarthritis who received vitamin D supplementation did not have a significant difference in knee pain or cartilage volume loss compared to patients who received placebo, according to a study appearing in the January 9 issue of JAMA.
"Knee osteoarthritis (OA) is a common age-related musculoskeletal disorder that has significant functional impact and has considerable societal costs through work loss, early retirement, and arthroplasty. Despite its impact, there are no medical treatments established to influence the course of the disease," according to background information in the article. "Some studies have suggested that vitamin D may protect against structural progression."
Timothy McAlindon, D.M., M.P.H., of Tufts Medical Center, Boston, and colleagues conducted a clinical trial to examine whether vitamin D supplementation is associated with reductions in symptomatic and structural progression of knee OA. The 2-year randomized, placebo-controlled clinical trial included 146 participants with symptomatic knee OA (average age, 62 years; 61 percent women), who were enrolled in the study between March 2006 and June 2009. Participants were randomized to receive either placebo or oral cholecalciferol, 2,000 IU/day, with dose escalation to increase serum levels to more than 36 ng/mL. Eighty-five percent of the participants completed the study.
The primary measured outcomes for the study were knee pain severity (Western Ontario and McMaster Universities [WOMAC] pain scale, 0-20: 0, no pain; 20, extreme pain), and cartilage volume loss measured by magnetic resonance imaging. Secondary outcomes included physical function, knee function (WOMAC function scale, 0-68: 0, no difficulty; 68, extreme difficulty), cartilage thickness, bone marrow lesions, and radiographic joint space width.
Serum 25-hydroxyvitamin D levels increased by an average 16.1 ng/mL in the treatment group and by an average 2.1 ng/mL in the placebo group. Knee pain at the beginning of the study was slightly worse in the treatment group (average, 6.9) than in the placebo group (average, 5.8). Knee function at the beginning of the study was significantly worse in the treatment group (average, 22.7) than in the placebo group (average, 18.5). In the subset analyses for the WOMAC pain outcome, the effects were generally similar, and nonsignificant. The researchers found that knee pain decreased in both groups by an average -2.31 in the treatment group and -1.46 in the placebo group, with no significant differences at any time. The percentage of cartilage volume decreased by the same extent in both groups, by about 4 percent. There were no differences in any of the secondary clinical end points.
There were 31 serious adverse events in the vitamin D group and 23 in the placebo group but the number of participants who experienced an event was 16 in each group.
"… additional results from epidemiologic studies that emerged during the course of this study have been mixed demonstrating positive and negative associations. Two studies appeared to show strong associations of bone density with the development of knee OA, but some of those investigators later published concerns about the possibility of such associations arising as a result of contingent confounding. Therefore, together with the results of this clinical trial, the overall data suggest that vitamin D supplementation at a dose sufficient to elevate 25-hydroxyvitamin D levels to more than 36 ng/mL does not have major effects on clinical or structural outcomes in knee OA, at least in a U.S. sample," the authors conclude.
###
(JAMA. 2013;309(2):155-162; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor's Note: This study was funded by a grant from the National Institutes of Health, NIAMS, and the Office of Dietary Supplements, a grant from the National Center for Research Resources, and a grant from the Houston Veterans Affairs Health Services Research and Development Service. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, etc.
To contact Timothy McAlindon, D.M., M.P.H., call Julie Jette at 617-636-3265 or email jjette@tuftsmedicalcenter.org.
END
CHICAGO – In an examination of the effectiveness of cefixime, the only oral cephalosporin antimicrobial recommended for treatment of Neisseria gonorrhoeae (gonorrhea) infections, researchers found a clinical treatment failure rate of nearly 7 percent for patients treated at a clinic in Toronto, according to a preliminary study published in the January 9 issue of JAMA.
"Because of Neisseria gonorrhoeae resistance to all prior first-line antimicrobial agents, cephalosporin [antibiotic] therapy with adjuvant azithromycin or doxycycline is recommended for treatment of gonorrhea," ...
CHICAGO – Among infants undergoing major surgery, postoperative use of intermittent intravenous paracetamol (acetaminophen) for the management of pain resulted in a lower cumulative morphine dose over 48 hours, according to a study appearing in the January 9 issue of JAMA.
Opioid therapy for the treatment of pain is associated with adverse effects. Researchers are seeking alternative analgesic regimens in neonates and infants, according to background information in the article. Paracetamol has been proposed as an alternative, with one study showing promise.
Ilse Ceelie, ...
Patients with non-small-cell lung cancer survive longer if they are taking beta-blockers while receiving radiotherapy, according to a study of 722 patients published in the cancer journal Annals of Oncology [1] today (Wednesday).
Researchers at the University of Texas MD Anderson Cancer Center (Houston, USA) reviewed the progress and outcomes of patients who had received radiotherapy as their main or first line of treatment for cancer (known as "definitive radiotherapy" i.e. radiotherapy that is delivered at doses of 60 Gy or more, with the intention of curing the disease). ...
A 'cheater' mutation (chtB) in Dictyostelium discoideum, a free living slime mould able to co-operate as social organism when food is scarce, allows the cheater strain to exploit its social partner, finds a new study published in BioMed Central's open access journal BMC Evolutionary Biology. The mutation ensures that when mixed with 'normal' Dictyostelium more than the fair share of cheaters become spores, dispersing to a new environment, and avoiding dying as stalk cells.
Dictyostelium have an unusual life style. They generally live as individual amoeboid cells, eating ...
Patients who take a triple combination of blood pressure drugs and common painkillers are at an increased risk of serious kidney problems, especially at the start of treatment, finds a study published on bmj.com today.
Although the absolute risk for individuals is low, it is still something doctors and patients should be aware of, say the researchers.
Acute kidney injury (also known as kidney failure) is a major public health concern. It occurs in more than 20% of hospital inpatients and is associated with around half of all potentially preventable deaths in hospital. ...
Breast and colorectal cancer screening should be targeted towards patients with a life expectancy greater than 10 years: for any shorter life expectancy the harms are likely to outweigh the benefits, concludes a study published on bmj.com today.
The authors stress that their results "should not be used to deny screening for patients with limited life expectancy" but "should inform decision making which aims to account for patient preferences and values while maximising benefits and minimising risks."
Guidelines recommend screening healthy older patients because complications ...
A special report published by the BMJ today finds that thousands of melanoma patients around the world are undergoing an expensive and invasive procedure called sentinel node biopsy, despite a lack of clear evidence and concerns that it may do more harm than good.
Although not recommended for routine use in England, it has become the standard care for melanoma patients in several countries including the United States, where it was estimated to cost over $686m in 2012.
Melanoma is the fifth most common cancer in the UK, affecting one in 60 people. In the US it affects ...
Male deaths from all-causes, but particularly cardiovascular and respiratory disease, could be significantly reduced with a decrease in biomass smoke (smoke produced by domestic cooking and heating and woodland fires), a paper published today on bmj.com suggests.
The researchers say this could have significant impact on further interventions to reduce pollution from this source.
Although a large amount of research has been carried out on the adverse health effects of air pollution, no studies have reported reductions in deaths associated with interventions to reduce ...
COLUMBUS, Ohio – An experimental oral drug given to mice after a spinal cord injury was effective at improving limb movement after the injury, a new study shows.
The compound efficiently crossed the blood-brain barrier, did not increase pain and showed no toxic effects to the animals.
"This is a first to have a drug that can be taken orally to produce functional improvement with no toxicity in a rodent model," said Sung Ok Yoon, associate professor of molecular & cellular biochemistry at Ohio State University and lead author of the study. "So far, in the spinal cord ...
A synthetic "poop" developed at the University of Guelph can cure nasty gastrointestinal infections caused by Clostridium difficile, a toxin-producing bacterium.
A study on the artificial stool was published today in the inaugural issue of Microbiome, a new peer-reviewed science journal.
The stool – a "super-probiotic" called RePOOPulate – was created by Guelph microbiologist Emma Allen-Vercoe to replace human fecal matter used in stool transplants, a known treatment for C. difficile.
She made the super-probiotic from purified intestinal bacterial cultures grown ...
